Xeris Biopharma Holdings (XERS) Cash from Investing Activities (2020 - 2026)

Xeris Biopharma Holdings has reported Cash from Investing Activities for 7 years, with the latest figure at -$325000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 2400.0% year-over-year to -$325000.0; the trailing twelve-month figure through Mar 2026 stood at -$1.0 million (down 104.11% YoY), and the FY2025 full-year result was -$696000.0, down 114.25% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$325000.0, up from -$333000.0 in the prior quarter.
• The five-year high for Cash from Investing Activities was $14.9 million in Q4 2023, with the low at -$44.0 million in Q1 2023.
• Historically, Cash from Investing Activities has averaged $1.9 million across 5 years, with a median of $6.7 million in 2022.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 118.44% — and 2026, when it tumbled 2400.0%.
• Xeris Biopharma Holdings' Cash from Investing Activities stood at $9.2 million in 2022, then soared by 62.17% to $14.9 million in 2023, then plunged by 32.63% to $10.0 million in 2024, then tumbled by 103.32% to -$333000.0 in 2025, then climbed by 2.4% to -$325000.0 in 2026.
• The last three Cash from Investing Activities figures came in at -$325000.0 (Q1 2026), -$333000.0 (Q4 2025), and -$71000.0 (Q3 2025), per Business Quant data.